Zatz M, Rapaport D, Vainzof M, Passos-Bueno M R, Bortolini E R, Pavanello R de C, Peres C A
Departamento de Biologia, Universidade de São Paulo, Brazil.
J Neurol Sci. 1991 Apr;102(2):190-6. doi: 10.1016/0022-510x(91)90068-i.
Serum creatine-kinase (CK) activities were determined in 536 patients affected with X-linked muscular dystrophy (456 with Duchenne or DMD and 80 with Becker or BMD) and serum pyruvate-kinase (PK) in 360 among them (309 DMD and 51 BMD). The aim of this investigation was to assess the variability and rate of decrease in serum activity in DMD as compared with BMD as a function of age and in DMD as a function of Vignos scale as well. In DMD, maximum CK and PK activities were found around 1-6 years old and the average rate of decline according to age was estimated as 0.18 per year and 0.27-0.29 for both enzymes as a function of Vignos scale (assessed in 291 cases). For BMD, maximum serum enzyme levels were found around 10-15 years old and the rate of decline of serum activity per year was 0.06 for CK and 0.07 for PK. If maximum levels of serum enzyme reflect active muscle degeneration and the rate of decline per year to progressive loss of muscle mass (responsible for the release of muscle enzymes to the blood stream) our observations suggest: (a) active muscle degeneration occurs, on average, 5 years later in the group of outliers and 10 years later in BMD as compared with severe DMD; (b) the rate in which muscle mass is lost is significantly greater in DMD than in BMD and therefore serum enzyme determinations may represent an important test for evaluation of therapeutic trials; (c) serum enzymes determination may represent an important preliminary test to discriminate in a proportion of young patients if they will develop a severe or milder phenotype.
对536例X连锁肌营养不良患者(456例杜氏肌营养不良症或DMD患者,80例贝克肌营养不良症或BMD患者)测定了血清肌酸激酶(CK)活性,并对其中360例患者(309例DMD患者和51例BMD患者)测定了血清丙酮酸激酶(PK)活性。本研究的目的是评估与BMD相比,DMD患者血清活性的变异性和下降速率,作为年龄的函数,以及在DMD中作为Vignos量表的函数。在DMD患者中,CK和PK的最大活性出现在1 - 6岁左右,根据年龄的平均下降速率估计为每年0.18,根据Vignos量表(在291例患者中评估),两种酶的平均下降速率为每年0.27 - 0.29。对于BMD患者,血清酶水平的最大值出现在10 - 15岁左右,CK每年的血清活性下降速率为0.06,PK为0.07。如果血清酶的最高水平反映活跃的肌肉变性,而每年的下降速率反映肌肉质量的逐渐丧失(导致肌肉酶释放到血流中),我们的观察结果表明:(a)与严重的DMD相比,在异常值组中活跃的肌肉变性平均发生时间晚5年,在BMD中晚10年;(b)DMD患者肌肉质量丧失的速率明显高于BMD患者,因此血清酶测定可能是评估治疗试验的重要检测方法;(c)血清酶测定可能是一项重要的初步检测,用于在一定比例的年轻患者中区分他们将发展为严重还是较轻的表型。